Abstract
Background
The role of enteric flora in the pathogenesis of inflammatory bowel disease constitutes the rationale for the use of antibiotics as adjuvant agents in the treatment of ulcerative colitis (UC) and Crohn's disease.
Objective
The aim of this study was to assess, in a preliminary fashion, the efficacy of the nonabsorbable antibiotic rifaximin in the treatment of exacerbation of UC in patients with a history of poor corticosteroid tolerance.
Methods
This open label pilot study was conducted in the Gastroenterology Unit, S. Raffaele University Hospital (Milan, Italy). Male and female patients aged 18 to 65 years with an established diagnosis of left-sided UC who were experiencing a clinical relapse during maintenance treatment with mesalamine and with a history of poor tolerance to corticosteroid therapy were included in the study. They received rifaximin 400 mg BID for 4 weeks while continuing to receive mesalamine 2.4 g/d. Disease activity before and after treatment was assessed using Rachmilewitz's Activity Index (RAI). A final RAI score <6 was considered clinical remission.
Results
Ten patients (9 men, 1 woman; mean [sd]age, 48.1 [12.3] years [range, 23–64 years]) participated in the study. The RAI decreased in all patients. Rifaximin treatment induced clinical remission in 7 patients (70%). No adverse effects were reported.
Conclusions
Due to our study design, no definitive Conclusions can be drawn. However, our preliminary data suggest that rifaximin may be beneficial in the treatment of active UC, obviating corticosteroid therapy in most cases.
Full Text
The Full Text of this article is available as a PDF (230.2 KB).
References
- 1.Balfour Sartor R. The role of luminal bacteria in colitis: More than an antigenic drive. Eur J Clin Invest. 1998;28:1027–1029. doi: 10.1046/j.1365-2362.1998.00404.x. [DOI] [PubMed] [Google Scholar]
- 2.Swidsinski A, Ladhoff A, Pernthaler A. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44–54. doi: 10.1053/gast.2002.30294. [DOI] [PubMed] [Google Scholar]
- 3.Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut. 2004;53:1–4. doi: 10.1136/gut.53.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Marteau P, Seksik P, Shanahan F. Manipulation of the bacterial flora in inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 2003;17:47–61. doi: 10.1053/bega.2002.0344. [DOI] [PubMed] [Google Scholar]
- 5.Gillis JC, Brogden RN. Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteriaDrugs. 1995;49:467–484. doi: 10.2165/00003495-199549030-00009. [DOI] [PubMed] [Google Scholar]
- 6.Shafran I, Johnson K, Hamm L, Murdock RH., Jr Efficacy and tolerability of rifaximin, a nonabsorbed oral antibiotic, in the treatment of active Crohn's disease: Results of an open-label study. Am J Gastroenterol. 2003;98:S250–s2. (Suppl) Abstract. [Google Scholar]
- 7.Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial. BMJ. 1989;298:82–86. doi: 10.1136/bmj.298.6666.82. [DOI] [PMC free article] [PubMed] [Google Scholar]